Related Experiment Video
Updated: Jul 28, 2025
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma
Min Yin1, Chunli Lu2, Huimei Zhou3
1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric and Gynecologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Objective:
Ovarian clear cell carcinoma (OCCC) is a distinct entity from epithelial ovarian cancer. The prognosis of advanced and recurrent disease is very poor due to resistance to chemotherapeutic agents. Our aim was to explore the molecular alterations among OCCC patients with different chemotherapeutic responses and to obtain insights into potential biomarkers.
Methods:
Twenty-four OCCC patients were included in this study. The patients were divided into two groups based on the relapse time after the first-line platinum-based chemotherapy: the platinum-sensitive group (PS) and the platinum-resistant group (PR). Gene expression profiling was performed using NanoString nCounter PanCancer Pathways Panel.
Results:
Gene expression analysis comparing PR vs. PS identified 32 differentially expressed genes: 17 upregulated genes and 15 downregulated genes. Most of these genes are involved in the PI3K, MAPK and Cell Cycle-Apoptosis pathways. In particular, eight genes are involved in two or all three pathways.
Conclusion:
The dysregulated genes in the PI3K, MAPK, and Cell Cycle-Apoptosis pathways identified and postulated mechanisms could help to probe biomarkers of OCCC platinum sensitivity, providing a research basis for further exploration of targeted therapy.
Insights
Molecular alterations in ovarian clear cell carcinoma (OCCC) were investigated. Gene expression profiling revealed key pathway differences between platinum-sensitive and platinum-resistant OCCC, offering potential biomarkers for targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Ovarian clear cell carcinoma (OCCC) is a distinct subtype of ovarian cancer with a poor prognosis, particularly in advanced or recurrent stages.
- Resistance to conventional chemotherapeutic agents, including platinum-based drugs, presents a significant clinical challenge in managing OCCC.
- Identifying molecular differences associated with chemotherapy response is crucial for developing effective treatment strategies and biomarkers.
Purpose of the Study:
- To explore molecular alterations in OCCC patients exhibiting varying responses to chemotherapy.
- To identify potential biomarkers that distinguish platinum-sensitive from platinum-resistant OCCC.
- To gain insights into the molecular mechanisms underlying chemotherapy resistance in OCCC.
Main Methods:
- Gene expression profiling was conducted on samples from 24 OCCC patients.
- Patients were categorized into platinum-sensitive (PS) and platinum-resistant (PR) groups based on relapse time after first-line platinum-based chemotherapy.
- The NanoString nCounter PanCancer Pathways Panel was utilized for gene expression analysis.
Main Results:
- Gene expression analysis identified 32 differentially expressed genes between PR and PS groups (17 upregulated, 15 downregulated).
- The majority of these genes are implicated in critical cellular pathways: PI3K, MAPK, and Cell Cycle-Apoptosis.
- A subset of eight genes was found to be involved in two or all three of these pathways, suggesting a complex molecular interplay.
Conclusions:
- Dysregulated genes within the PI3K, MAPK, and Cell Cycle-Apoptosis pathways are associated with platinum resistance in OCCC.
- These identified genes and their associated mechanisms represent potential biomarkers for predicting OCCC platinum sensitivity.
- The findings provide a foundation for further research into targeted therapeutic strategies for OCCC.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
